Investigating future therapies

Our scientists are committed to developing new therapies for patients with serious genetic diseases that are not well managed with current treatments.

Developing these novel genomic therapies requires years of laboratory research and clinical testing to evaluate their safety and efficacy. Volunteers who enroll in clinical trials help Sangamo researchers understand the potential benefits and risks of these investigational therapies in humans. Investigational therapies must pass through three phases of clinical before they can be approved for medicinal use.

Sangamo is conducting several clinical trials to evaluate the safety, tolerability and potential efficacy of its novel genomic therapies for rare blood and lysosomal storage disorders. Please visit the clinical study websites below or go to clinicaltrials.gov to learn more about our ongoing clinical trials.

Hemophilia B: FIXtendz Study

We are currently conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability and preliminary efficacy of SB-FIX in hemophilia B. For more information about our hemophilia B clinical trial and our SB-FIX genome editing approach for treatment of hemophilia B, please visit our study website at https://www.fixtendztrial.com.

Additionally, Clinicaltrials.gov provides an overview of all our ongoing clinical trials.

ASP0101_Hemo B_ FIXTENDZ.svg

Hemophilia A: Alta Study

Sangamo is conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy in hemophilia A. For more information about our hemophilia A clinical trial and our SB-525 gene therapy approach for treatment of hemophilia A, please visit our study website at http://www.altaclinicalstudy.com.

Additionally,Clinicaltrials.gov provides an overview of all our ongoing clinical trials.

SAN-9501 Clinical Trial Logo Design V6RM OL_Artboard 9.svg

Beta-Thalassemia: Thales Study

Sangamo is conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ST-400 in managing beta thalassemia. For more information about our beta thalassemia clinical trial and our ST-400 cell therapy approach for treatment of beta thalassemia, please visit our study website at http://www.thalesclinicalstudy.com.


Additionally, Clinicaltrials.gov provides an overview of all our ongoing clinical trials.

SAN-9501 Clinical Trial Logo Design V6RM OL_Artboard 9.svg

MPS I: EMPOWERS Study

Sangamo is conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of SB-318 in MPS I. For more information about our MPS I clinical trial and our SB-318 genome editing approach for treatment of MPS I, please visit our study website at http://www.empowersmpstrial.com.

Additionally, Clinicaltrials.gov provides an overview of all our ongoing clinical trials.

ASP0101_eMPowerS_Logo.svg

MPS II: CHAMPIONS Study

Sangamo is conducting a Phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of SB-913 in MPS II. For more information about our MPS II clinical trial and our SB-913 genome editing approach for treatment of MPS II, please visit our study website at http://mps2study.com.


Additionally, Clinicaltrials.gov provides an overview of all our ongoing clinical trials.

ASP0136_MPS2-chaMPionS_Logo.svg

Legacy Clinical Research

 

Infectious Diseases


HIV/AIDS: SB-728mR-HSPC

Sangamo’s HIV/AIDS program is an investigator sponsored Phase 1/2 clinical trial to evaluate the safety, tolerability and preliminary efficacy of SB-728mR-HSPC. Please visit clinicaltrials.gov to learn more about our ongoing and past clinical trials.